Kodiak Sciences (NASDAQ:KOD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kodiak Sciences (NASDAQ:KOD) from a sell rating to a hold rating in a research report sent to investors on Friday.

Other equities analysts also recently issued reports about the stock. Barclays raised shares of Kodiak Sciences from an “underweight” rating to an “equal weight” rating and increased their price target for the stock from $7.00 to $17.00 in a research note on Thursday. HC Wainwright raised their target price on Kodiak Sciences from $3.00 to $5.00 and gave the company a “neutral” rating in a research note on Monday, August 18th. Jefferies Financial Group assumed coverage on Kodiak Sciences in a research note on Monday, September 22nd. They issued a “buy” rating and a $15.00 price target on the stock. Finally, JPMorgan Chase & Co. raised Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price objective for the company in a research report on Thursday, August 14th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Kodiak Sciences currently has an average rating of “Hold” and a consensus price target of $13.00.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $15.80 on Friday. The stock has a market cap of $834.56 million, a P/E ratio of -4.16 and a beta of 2.44. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $19.39. The stock has a 50 day simple moving average of $9.41 and a two-hundred day simple moving average of $5.63.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). Sell-side analysts predict that Kodiak Sciences will post -3.45 earnings per share for the current year.

Hedge Funds Weigh In On Kodiak Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC boosted its stake in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. US Bancorp DE raised its holdings in Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after buying an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. bought a new position in shares of Kodiak Sciences in the first quarter worth approximately $28,000. Public Employees Retirement System of Ohio lifted its stake in shares of Kodiak Sciences by 183.9% in the fourth quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company’s stock worth $147,000 after buying an additional 9,560 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Kodiak Sciences by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock valued at $56,000 after buying an additional 2,691 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.